相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer
Christine Mayer et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2016)
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Daniel D. Von Hoff et al.
CLINICAL CANCER RESEARCH (2016)
Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent
Ashish Saxena et al.
MEDICAL ONCOLOGY (2016)
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles
Afonso A. Shiozaki et al.
CLINICS (2016)
Clinical Research on Albumin-Bound Paclitaxel-Based Chemotherapy for Advanced Esophageal Cancer
Yuan Yuan et al.
Asian Pacific Journal of Cancer Prevention (2015)
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
T. C. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Edgar Perez-Herrero et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
Raffaella Palumbo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
A Biocompatible Reconstituted High-Density Lipoprotein Nano-System as a Probe for Lung Cancer Detection
Hongxiu Lu et al.
MEDICAL SCIENCE MONITOR (2015)
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial
Ines Wasle et al.
ANNALS OF HEMATOLOGY (2015)
Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials
Meiyuan Xing et al.
PLOS ONE (2015)
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy
Jianliang Yang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
Devalingam Mahalingam et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
Yasutsuna Sasaki et al.
CANCER SCIENCE (2014)
Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer
Sebastian Strieth et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
Peter J. Hosein et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
A. H. Ko et al.
BRITISH JOURNAL OF CANCER (2013)
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
John F. Deeken et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2013)
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70 years)
Umberto Basso et al.
JOURNAL OF GERIATRIC ONCOLOGY (2013)
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
Jeffrey R. Infante et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
David S. Alberts et al.
GYNECOLOGIC ONCOLOGY (2012)
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
Shih-Hung Yang et al.
INVESTIGATIONAL NEW DRUGS (2012)
Doxil® - The first FDA-approved nano-drug: Lessons learned
Yechezkel (Chezy) Barenholz
JOURNAL OF CONTROLLED RELEASE (2012)
Pegylated Liposomal Doxorubicin A Review of its use in Metastatic Breast Cancer, Ovarian Cancer, Multiple Myeloma and AIDS-Related Kaposi's Sarcoma
Sean T. Duggan et al.
DRUGS (2011)
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Maria Volkova et al.
CURRENT CARDIOLOGY REVIEWS (2011)
Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors
Raquel S. Teixeira et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2010)
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
Monica Mita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study
Luis A. Pires et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies
William C. Zamboni et al.
CLINICAL CANCER RESEARCH (2009)
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
Leonard W. Seymour et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Michael G. Teneriello et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study
Paul Sabbatini et al.
GYNECOLOGIC ONCOLOGY (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Nanoparticles for drug delivery in cancer treatment
Barbara Haley et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
Keun Seok Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
Nancy U. Lin et al.
INVESTIGATIONAL NEW DRUGS (2007)
Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers
Maria L. N. Dias et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
NM Kuderer et al.
CANCER (2006)
Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE
KV Pinheiro et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
AV Boddy et al.
CLINICAL CANCER RESEARCH (2005)
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: Results of a phase II study
Donald A. Richards et al.
CLINICAL LUNG CANCER (2005)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
NK Ibrahim et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Liposomal encapsulated anti-cancer drugs
RD Hofheinz et al.
ANTI-CANCER DRUGS (2005)
Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma
CHM Azevedo et al.
GYNECOLOGIC ONCOLOGY (2005)
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer
MV Seiden et al.
GYNECOLOGIC ONCOLOGY (2004)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer
Y Matsumura et al.
ANNALS OF ONCOLOGY (2004)
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
K Gelmon et al.
INVESTIGATIONAL NEW DRUGS (2004)
Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis
J Rejman et al.
BIOCHEMICAL JOURNAL (2004)
Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease
VTM Hungria et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients
RC Maranhao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Uptake of a cholesterol-rich emulsion by breast cancer
SR Graziani et al.
GYNECOLOGIC ONCOLOGY (2002)
Phase I and Pharmacologic study of liposomal lurtotecan, NX 211: Urinary excretion predicts hematologic toxicity
DFS Kehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues
A Ades et al.
GYNECOLOGIC ONCOLOGY (2001)
Phase I study of liposomal annamycin
DJ Booser et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Pegylated liposomal doxorubicin (doxil):: Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
T Safra et al.
ANNALS OF ONCOLOGY (2000)
Phase II study of liposomal doxorubicin in advanced gynecologic cancers
VP Israel et al.
GYNECOLOGIC ONCOLOGY (2000)
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial
AH Sarris et al.
ANNALS OF ONCOLOGY (2000)
分享论文
